Skip to main content
Premium Trial:

Request an Annual Quote

Heart Disease Edits

Researchers from Verve Therapeutics have used gene editing to turn off in monkeys two genes associated with high cholesterol and triglyceride levels, the New York Times reports. This, it adds, could portend a one-time treatment to some day prevent heart disease.

According to the Times, the firm used a gene-editing approach aimed at PCSK9 and ANGPTL3, which encode proteins that regulate LDL cholesterol and triglycerides, respectively. The approach was tested in 13 monkeys and, so far, appears to lead to a 59 percent decrease in LDL levels and a 64 percent decrease in triglyceride levels, the Times reports. The results were presented during the International Society for Stem Cell Research, which was held virtually this year, it adds.

While the University of Chicago's Michael Davidson tells the Times the approach "could be the cure for heart disease," it notes that the monkeys need to be monitored for side effects and any indications of off-target gene editing, as well as to gauge how long the treatment lasts. It could be years before any trials in humans begin, the Times adds.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.